Home
AskBio

AskBio Market Share Analysis for May 2026

AskBio's researchers have defined how genetic medicine will be commercialized in the future. Learn more about our innovative gene therapy technology and how you can collaborate with us.

Health > Biotechnology and Pharmaceuticals

Domainaskbio.com

Year Founded2001

Employees501 - 1000

Annual Revenue$15M - $25M

AskBio

AskBio (including company regionals)

askbio.com

See more website traffic and engagement information

AskBio Revenue up to May 2026 is 15M - 25M

revenue generated by AskBio top domains

AskBio top domains revenue over 3 years

Revenue for AskBio top domains

askbio.com15M - 25M

See more with Sales Intelligence

Total visits to AskBio's top domains

Understand AskBio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

askbio.com14.4K

See more with Sales Intelligence

Avg. visit duration in AskBio's top domains

Analyze AskBio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

askbio.com00:00:46

See more with Sales Intelligence

Avg. pageviews on AskBio's top domains

See how AskBio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

askbio.com1.96

See more with Sales Intelligence

AskBio top competitors by domain

Top similar sites in May 2026, ranked by their affinity

regenxbio.comCompany NameREGENXBIOEmployees201 - 500HQUnited States, Maryland, RockvilleAnnual revenue$100M - $200MTotal visits25.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by AskBio

These are the website technologies, by industry, used by AskBio top domains

Content Management System (4)

WordPress

Mobile (3)

Meta Viewport

Widget (3)

Twemoji

Advertising (2)

DoubleClick

More Technologies

8

See all

News & Signals from AskBio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAskBio Asklepios BioPharmaceutical, Inc. is developing potentially durable gene therapy approach for the rare neuromuscular disorder.AskBio has dosed the first participant in PROGRESS-GT LOPD, a Phase 1/Phase 2 clinical trial evaluating investigational gene therapy AB-1009 for the treatment of late-onset Pompe disease (LOPD).[1] The milestone advances the company's efforts to develop a potentially durable gene therapy approach for the rare neuromuscular disorder, which continues to present significant unmet medical needs despite the availability of enzyme replacement therapies (ERTs).

NewsAskBio Asklepios BioPharmaceutical, Inc. partnered with Austrianova Thailand Co. on Mar 1st '26.Avaí Bio recently announced that it has initiated manufacturing of a master cell bank of genetically modified cells that overexpress the α-Klotho protein, working alongside joint venture partner Austrianova through their shared entity, Klothonova.

NewsAskBio Asklepios BioPharmaceutical, Inc. attends event Cell Therapy 32nd Annual Meeting.AskBio announces 6 presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting.